0

Spasticity Treatment Market by Type and Geography - Forecast and Analysis 2022-2026

  • Published: Mar 2022
  • Pages: 120
  • SKU: IRTNTR72357
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The spasticity treatment market share is expected to increase by USD 1.11 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 4.17%.

This spasticity treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers spasticity treatment market segmentation by type (drug therapy and physical therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The spasticity treatment market report also offers information on several market vendors, including Allergan Plc, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Covis Pharma BV, Dr. Reddys Laboratories Ltd., Endo International Plc, F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Ipsen Pharma, Jazz Pharmaceuticals Plc, Mayne Pharma Group Ltd., Merz Pharma GmbH and Co. KGaA, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., US WorldMeds, Cadila Healthcare Ltd., Medtronic Plc, and JPN Pharma Pvt. Ltd. among others.

What will the Spasticity Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Spasticity Treatment Market Size for the Forecast Period and Other Important Statistics

 

Spasticity Treatment Market: Key Drivers, Trends, and Challenges

The growing incidence of chronic diseases and health conditions is notably driving the spasticity treatment market growth, although factors such as long time taken to gain benefits in physical therapy may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the spasticity treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Spasticity Treatment Market Driver

  • The growing incidence of chronic diseases and health conditions is one of the key drivers supporting the spasticity treatment market growth. 
  • The prevalence of chronic neuro-musculoskeletal disorders is increasing worldwide, which in turn, is increasing the incidence of spasticity.
  • For instance, as per the Multiple Sclerosis Trust, about 2.5 million people around the world suffer from multiple sclerosis. 
  • Spinal cord injury and traumatic brain injury are caused by external conditions that cause damage to the spinal cord and brain, respectively. Moreover, the high prevalence of these conditions globally is because of the increase in the number of falls, road accidents, assaults, and other causes. Spasticity was diagnosed in more than 50%-60% of these cases.

Thus, the strong correlation between the above chronic conditions and spasticity helps the global spasticity treatment market benefit from the increasing incidence of these chronic conditions. Such growing incidence will drive market growth during the forecast period.

Key Spasticity Treatment Market Trend

  • The advent of neurostimulation devices is another factor supporting the spasticity treatment market growth. 
  • The management of spasticity sometimes poses an unresolvable challenge due to the unmet need in the market.
  • Drug and physical treatments for the management of spasticity only offer short-term efficacy.
  • The therapies are sometimes compounded by adverse side effects, which are often unpleasant for the patient. Hence, to overcome this situation, many vendors in the market are developing devices, specifically neurostimulation devices, to treat spasticity in combination with the medications available. 

Thus, the introduction of such new devices in the global spasticity treatment market will attract the attention of the patients and healthcare practitioners and hence, drive the market in the future.

Key Spasticity Treatment Market Challenge

  • The long time taken to gain benefits in physical therapy is one of the factors hindering the spasticity treatment market growth. 
  • For instance, the cost of a single session of physical therapy in the US is $100-$150.
  • The treatment includes various types of therapy such as electronic stimulation, functional training, manual therapy, and therapeutic exercise. All these vary in cost, which can be $75-$135 for 15 minutes.
  • All costs are not covered by insurance because physical therapy falls under the category of services. The average Medicare allowable for services is $26-$30 per weighted procedure. Thus, patients have to pay 70%-75% of the cost from their pockets.

Hence, limitations such as the long duration of physical therapy coupled with its high treatment costs and differences in service delivery create a negative impact on the segment, thereby posing a challenge to the market.

This spasticity treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global spasticity treatment market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the spasticity treatment market during the forecast period.

Who are the Major Spasticity Treatment Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Allergan Plc
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Covis Pharma BV
  • Dr. Reddys Laboratories Ltd.
  • Endo International Plc
  • F. Hoffmann La Roche Ltd.
  • Hikma Pharmaceuticals Plc
  • Ipsen Pharma
  • Jazz Pharmaceuticals Plc
  • Mayne Pharma Group Ltd.
  • Merz Pharma GmbH and Co. KGaA
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Unichem Laboratories Ltd.
  • US WorldMeds
  • Cadila Healthcare Ltd.
  • Medtronic Plc
  • JPN Pharma Pvt. Ltd.

 

This statistical study of the spasticity treatment market encompasses successful business strategies deployed by the key vendors. The spasticity treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

Alembic Pharmaceuticals Ltd.

  • The company offers BOTOX which takes a different approach than oral medications. BOTOX is injected by a doctor into specific muscles within the body that have been affected by Spasticity which helps reduce muscle stiffness. 

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The spasticity treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Spasticity Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the spasticity treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Spasticity Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market’s growth will originate from North America during the forecast period. The US is the key market for spasticity treatment market in North America. Market growth in this region will be slower than the growth of the market in Asia.

The increase in the high-risk factors for spasticity in the region will facilitate the spasticity treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 is expected to have an adverse impact on the growth of the spasticity treatment market. However, the increasing prevalence of neurological disorders and government support in the region to maintain a consistent supply of medicines will lead to a recovery in the market growth during the forecast period.

What are the Revenue-generating Type Segments in the Spasticity Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The spasticity treatment market share growth by the drug therapy segment will be significant during the forecast period. Antispasmodic agents such as baclofen or acetylcholine release inhibitors such as onabotulinumtoxinA remain the first line of drug treatment for spasticity. For instance, as per the Centers for Disease Control and Prevention (CDC), every year, more than 795,000 people in the US have a stroke. About half of the people who survive after having a stroke suffer from muscle spasticity. Similarly, the prevalence of other conditions further increases the risk of spasticity. As drug therapy is easily accessible to most patients, it naturally becomes the first choice of treatment, which, thus, makes it the segment with the larger share in the global spasticity treatment market.

This report provides an accurate prediction of the contribution of all the segments to the growth of the spasticity treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Spasticity Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 4.17%

Market growth 2022-2026

$ 1.11 billion

Market structure

Fragmented

YoY growth (%)

3.65

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Allergan Plc, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Covis Pharma BV, Dr. Reddys Laboratories Ltd., Endo International Plc, F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Ipsen Pharma, Jazz Pharmaceuticals Plc, Mayne Pharma Group Ltd., Merz Pharma GmbH and Co. KGaA, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., US WorldMeds, Cadila Healthcare Ltd., Medtronic Plc, and JPN Pharma Pvt. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Spasticity Treatment Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive spasticity treatment market growth during the next five years
  • Precise estimation of the spasticity treatment market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the spasticity treatment industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of spasticity treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Type

    • 5.1 Market segments
      • Exhibit 24: Chart on Type - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
    • 5.2 Comparison by Type
      • Exhibit 26: Chart on Comparison by Type
      • Exhibit 27: Data Table on Comparison by Type
    • 5.3 Drug therapy - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Drug therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Drug therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Drug therapy - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Drug therapy - Year-over-year growth 2021-2026 (%)
    • 5.4 Physical therapy - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Physical therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Physical therapy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Physical therapy - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Physical therapy - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Type
      • Exhibit 36: Market opportunity by Type ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 40: Chart on Geographic comparison
      • Exhibit 41: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 UK - Market size and forecast 2021-2026
      • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.10 China - Market size and forecast 2021-2026
      • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.11 Japan - Market size and forecast 2021-2026
      • Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 78: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 81: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 82: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 83: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 84: Matrix on vendor position and classification
            • 10.3 Alembic Pharmaceuticals Ltd.
              • Exhibit 85: Alembic Pharmaceuticals Ltd. - Overview
              • Exhibit 86: Alembic Pharmaceuticals Ltd. - Product / Service
              • Exhibit 87: Alembic Pharmaceuticals Ltd. - Key offerings
            • 10.4 Cadila Healthcare Ltd.
              • Exhibit 88: Cadila Healthcare Ltd. - Overview
              • Exhibit 89: Cadila Healthcare Ltd. - Business segments
              • Exhibit 90: Cadila Healthcare Ltd. - Key news
              • Exhibit 91: Cadila Healthcare Ltd. - Key offerings
              • Exhibit 92: Cadila Healthcare Ltd. - Segment focus
            • 10.5 Dr. Reddys Laboratories Ltd.
              • Exhibit 93: Dr. Reddys Laboratories Ltd. - Overview
              • Exhibit 94: Dr. Reddys Laboratories Ltd. - Business segments
              • Exhibit 95: Dr. Reddys Laboratories Ltd. - Key offerings
              • Exhibit 96: Dr. Reddys Laboratories Ltd. - Segment focus
            • 10.6 Endo International Plc
              • Exhibit 97: Endo International Plc - Overview
              • Exhibit 98: Endo International Plc - Business segments
              • Exhibit 99: Endo International Plc - Key news
              • Exhibit 100: Endo International Plc - Key offerings
              • Exhibit 101: Endo International Plc - Segment focus
            • 10.7 Hikma Pharmaceuticals Plc
              • Exhibit 102: Hikma Pharmaceuticals Plc - Overview
              • Exhibit 103: Hikma Pharmaceuticals Plc - Business segments
              • Exhibit 104: Hikma Pharmaceuticals Plc - Key offerings
              • Exhibit 105: Hikma Pharmaceuticals Plc - Segment focus
            • 10.8 Ipsen Pharma
              • Exhibit 106: Ipsen Pharma - Overview
              • Exhibit 107: Ipsen Pharma - Business segments
              • Exhibit 108: Ipsen Pharma - Key offerings
              • Exhibit 109: Ipsen Pharma - Segment focus
            • 10.9 Mayne Pharma Group Ltd.
              • Exhibit 110: Mayne Pharma Group Ltd. - Overview
              • Exhibit 111: Mayne Pharma Group Ltd. - Business segments
              • Exhibit 112: Mayne Pharma Group Ltd. - Key news
              • Exhibit 113: Mayne Pharma Group Ltd. - Key offerings
              • Exhibit 114: Mayne Pharma Group Ltd. - Segment focus
            • 10.10 Medtronic Plc
              • Exhibit 115: Medtronic Plc - Overview
              • Exhibit 116: Medtronic Plc - Business segments
              • Exhibit 117: Medtronic Plc - Key news
              • Exhibit 118: Medtronic Plc - Key offerings
              • Exhibit 119: Medtronic Plc - Segment focus
            • 10.11 Merz Pharma GmbH and Co. KGaA
              • Exhibit 120: Merz Pharma GmbH and Co. KGaA - Overview
              • Exhibit 121: Merz Pharma GmbH and Co. KGaA - Product / Service
              • Exhibit 122: Merz Pharma GmbH and Co. KGaA - Key offerings
            • 10.12 Pfizer Inc.
              • Exhibit 123: Pfizer Inc. - Overview
              • Exhibit 124: Pfizer Inc. - Business segments
              • Exhibit 125: Pfizer Inc. - Key news
              • Exhibit 126: Pfizer Inc. - Key offerings
              • Exhibit 127: Pfizer Inc. - Segment focus

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 128: Inclusions checklist
                • Exhibit 129: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 130: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 131: Research methodology
                • Exhibit 132: Validation techniques employed for market sizing
                • Exhibit 133: Information sources
              • 11.5 List of abbreviations
                • Exhibit 134: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your FREE sample now!
              The spasticity treatment market growth will increase by $1117.63 million during 2021-2026.
              The spasticity treatment market is expected to grow at a CAGR of 4.17% during 2021-2026.
              Technavio has segmented the spasticity treatment market by type (Drug therapy and Physical therapy) and geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Allergan Plc, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Covis Pharma BV, Dr. Reddys Laboratories Ltd., Endo International Plc, F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Ipsen Pharma, Jazz Pharmaceuticals Plc, Mayne Pharma Group Ltd., Merz Pharma GmbH and Co. KGaA, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., US WorldMeds, Cadila Healthcare Ltd., Medtronic Plc, JPN Pharma?áPvt. Ltd. are a few of the key vendors in the spasticity treatment market.
              North America will register the highest growth rate of 40.87% among the other regions. Therefore, the spasticity treatment market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the spasticity treatment market growth are:
              • Growing incidence of chronic diseases and health conditions
              • Advent of neurostimulation devices
              The spasticity treatment market vendors should focus on grabbing business opportunities from the drug therapy segment as it accounted for the largest market share in the base year.
              Safe and Secure SSL Encrypted
              Technavio

              Single User:

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Want to customize this report?

              This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

              We offer $1000 worth of FREE customization at the time of purchase
              Technavio
              Enquire Before Buying
              1. Home
              2. Health Care
              3. Published Report
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>